SagaX

SagaX is a pre-clinical stage biotechnology company focused on the development of engineered extracellular vesicles (EVs) for targeted therapeutic delivery. Founded by pioneers in the field of exosome biology from Massachusetts General Hospital and Harvard Medical School, the company leverages a proprietary platform to load EVs with diverse cargoes, including nucleic acids and proteins. SagaX aims to overcome the limitations of traditional delivery vehicles, such as viral vectors and lipid nanoparticles, by utilizing the natural biocompatibility and targeting capabilities of EVs. The company's primary therapeutic focus areas include oncology and neurodegenerative disorders, with a particular emphasis on crossing biological barriers like the blood-brain barrier.